R

Retina Centre of Ottawa | Ottawa, Canada

Research site

(Unclaimed)

Location

2211 Carling Avenue, Ottawa, Ontario, Canada

Site insights

Top conditions

Top treatments

APL-2

Dexamethasone

Zimura

ANX007

Pegcetacoplan

Avacincaptad pegol

IBE-814

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling

Geographic Atrophy

Drug: ANX007

Other: Sham Administration

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Biological: Aflibercept (EYLEA®)

Genetic: ABBV-RGX-314 Dose 2